In a randomized trial of 60 adults with metabolic dysfunction-associated steatotic liver disease, eating 400 g/day of whole Navelina oranges for four weeks did not significantly change fasting glucose, insulin, HOMA-IR or QUICKI relative to controls who avoided oranges. Fructosamine, a marker of short-term glycemic exposure, drifted downward without reaching significance (p = 0.078). Dietary sugar, vitamin A and vitamin C intake rose as expected. Within the orange arm, LDL changes tracked with HOMA-IR and insulin changes.
The headline result is reassuring in one direction and inconclusive in the other. Adding roughly four to five oranges daily, a substantial sugar load, did not worsen insulin sensitivity, which fits the broader evidence that whole fruit behaves differently from juice or added sugars because fiber and flavanones such as hesperidin blunt glycemic impact. But the trial gives no proof of benefit. Sixty participants over four weeks is underpowered for subtle metabolic shifts, and the fructosamine trend is a hypothesis, not a finding. The unblinded design and no-orange control invite behavioral confounding, and the LDL-HOMA-IR correlations are exploratory, within one arm, and prone to chance. Practically, adults with fatty liver need not fear whole fruit, though this trial cannot recommend oranges as a therapy. Treat it as a safety signal and pilot study; larger, longer trials with liver fat or enzyme endpoints would be needed to say anything about disease outcomes.